Results 161 to 170 of about 392,629 (269)
Chromosomal Instability Drives Glioblastoma Heterogeneity and Therapeutic Opportunities
ABSTRACT Glioblastoma, the most aggressive and lethal form of brain cancer, is defined by profound genomic instability, with Chromosomal Instability (CIN) playing a central role in driving tumor progression, therapy resistance, and poor prognosis. CIN is characterized by numerical and structural alterations, is driven by mechanisms such as mitotic ...
Amarnath Pal +3 more
wiley +1 more source
Systemic pre-conditioning favors effector over exhausted CD8 T-cell subsets following Sup2-IL33 armored CAR T-cell therapy. [PDF]
Ferry SL +9 more
europepmc +1 more source
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai +15 more
wiley +1 more source
The Conflicting Role of Myeloid Cells in CAR T-Cell Therapy. [PDF]
DeFranco G, Siegler EL, Kenderian SS.
europepmc +1 more source
ABSTRACT Acute pancreatitis (AP) begins with pancreatic local inflammation, leading to the onset of systemic inflammatory response syndrome (SIRS), followed by compensatory anti‐inflammatory response syndrome (CARS), which causes immune paralysis and higher mortality rate.
Liwei Liu +15 more
wiley +1 more source
Systematic optimization of PD-L1 and CLDN18.2 CAR-T designs identifies a bicistronic dual-target, double-CD3ζ architecture with enhanced antitumor activity in gastric cancer. [PDF]
Zhang X, Kong YJ, Li JY, Li HH, Chen L.
europepmc +1 more source
ABSTRACT Orthogonal translation systems (OTSs) enable site‐specific incorporation of non‐canonical amino acids (ncAAs) and are central to genetic code expansion. Current engineering strategies typically rely on hyperstable aminoacyl tRNA synthetase (aaRS) scaffolds to tolerate destabilizing mutations required for substrate diversification.
Nikolaj G. Koch +4 more
wiley +1 more source
Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases. [PDF]
Zhou S +9 more
europepmc +1 more source

